Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...

Elevation Oncology (ELEV) announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug ...

Shares of Elevation Oncology , Inc. (NASDAQ: ELEV) fell by 20% following the announcement that the company will discontinue the development of its drug candidate EO-3021. The decision came after ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Elevation Oncology (NASDAQ:ELEV) stock drops as the company shifts focus to solid tumor therapy EO-1022, halts EO-3021 development after weak data. Read more here.

Elevation Oncology (ELEV) had cash, cash equivalents and marketable securities totaling $93.2M vs. $83.1M as of ...